Acquired resistance is defined as when EGFR-mutant NSCLC patients achieved a response or stable disease with greater than six months of targeted therapy and subsequently developed disease progression while still on the targeted agent [22]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.